Hossam El Benawi on Comparison of DOACs and VKAs in the Treatment of Left Ventricular Thrombi
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn:
”The optimal duration of anticoagulation for left ventricular thrombus (LVT) remains unclear.
The 2022 AHA guidelines recommend treatment with a VKA or DOAC for at least 3–6 months, with longer therapy considered if needed.
However, evidence is limited.
Key questions include:
- What is the ideal duration of anticoagulation for LVT resolution?
- Do DOACs and VKAs differ in their effectiveness at resolving LVT?
Insights from our analysis (Mayo Clinic’s Multi-site LVT Study):
At 6 months post-LVT diagnosis, LVT resolution: 61% of patients treated with DOAC vs 61% treated with VKA (p = 1.0). Figure A.
20% of patients on DOAC required longer than 6 months for LVT resolution, compared to 26% of those on VKA ( p=0.31). Figure B.
The median time to LVT resolution was similar (DOAC: 96 days [IQR:67-180] and VKA: 102 days [IQR:68 -199], p = 0.22)
Despite anticoagulation therapy, Persistent LVT was 19.6% of the DOAC group and 13% of the VKA group (p=0.23). Figure B.
These findings suggest that a subset of LVT patients may need prolonged therapy (>6 months), underscoring the importance of tailored treatment strategies based on individual patient clinical characteristics.”
Read the full article here.
Article: Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi, A Retrospective Cohort Study
Authors: Hossam El Benawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls